Literature DB >> 3758204

Colcemid inhibits growth during early G1 in normal but not in tumorigenic lymphocytes.

A L Kenter, J V Watson, T Azim, T H Rabbitts.   

Abstract

Mitogenically stimulated human and mouse lymphocytes enter the cell cycle (G0, G1A, G1B, S, G2+M) via a newly recognized subphase, G1'. This subphase precedes G1A and is distinct from G0. The G1' subphase is absent in immortalized and tumorigenic lymphoblastoid cell lines (LCLs) by cytofluorimetric criteria. Furthermore, colcemid inhibits transition through the G0/G1' as well as G2 phases in mitogen-stimulated lymphocytes and in LCLs. Tumorigenic LCLs are not sensitive to growth inhibition by colcemid during early G1. These observations suggest that a progressive series of changes have occurred during G0/G1' which lead to deregulation of growth control.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3758204     DOI: 10.1016/0014-4827(86)90220-x

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  4 in total

1.  Detection of an immunoglobulin switch region-specific DNA-binding protein in mitogen-stimulated mouse splenic B cells.

Authors:  R A Wuerffel; A T Nathan; A L Kenter
Journal:  Mol Cell Biol       Date:  1990-04       Impact factor: 4.272

2.  Analysis of immunoglobulin Sgamma3 recombination breakpoints by PCR: implications for the mechanism of isotype switching.

Authors:  J Du; Y Zhu; A Shanmugam; A L Kenter
Journal:  Nucleic Acids Res       Date:  1997-08-01       Impact factor: 16.971

3.  High expression of a 3'----5' exonuclease activity is specific to B lymphocytes.

Authors:  A L Kenter; J Tredup
Journal:  Mol Cell Biol       Date:  1991-09       Impact factor: 4.272

4.  Switch recombination breakpoints are strictly correlated with DNA recognition motifs for immunoglobulin S gamma 3 DNA-binding proteins.

Authors:  R Wuerffel; C E Jamieson; L Morgan; G V Merkulov; R Sen; A L Kenter
Journal:  J Exp Med       Date:  1992-08-01       Impact factor: 14.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.